fig1

Figure 1. Schematic representation of miR-218 mechanisms of action. miR-218 targets multiple oncogenic cascades, transcription factors, apoptotic pathways, and cellular properties such as tumor development and metastasis, glucose uptake, and EMT, as well as reduces its own synthesis by inhibiting pri-miR-218. ERO1A: Endoplasmic reticulum oxidoreductase 1 alpha; VEGF: vascular endothelial growth factor; PI3K/AKT/mTOR: phosphoinositide 3-Kinase/protein kinase B/mammalian target of rapamycin; IL-6/JAK/STAT3: interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3; CCAT1: colon cancer-associated transcript 1; BMI-1: B lymphoma Mo-MLV insertion region 1 homolog; PTEN/YY1: phosphatase and tensin homolog/Yin Yang 1; PARP: poly-ADP ribose polymerase; Bcl-2: B-cell lymphoma; Mcl1: myeloid cell leukemia sequence 1; HOXA1: homeobox A1; RUNX2: runt-related transcription factor 2; PRKDC: protein kinase, DNA-activated, catalytic subunit; RPTPα: receptor protein tyrosine phosphatase alpha; SLIT2/SLIT3: Slit Guidance Ligand 2/3; TRIM9: tripartite motif 9; SNHG12: small nucleolar RNA host gene 12; SHMT1: serine hydroxymethyltransferase 1; CDCP1: CUB-domain-containing protein 1; ADAM9: disintegrin and metalloproteinase domain 9; HMGB1: high mobility group box-1; PXN: paxillin; EGFR: epidermal growth factor receptor; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PFK1: phosphofructokinase 1; GLUT1: glucose transporter 1; G6PD: glucose-6-phosphate dehydrogenase; HK2: hexokinase 2; MEF2D: myocyte enhancer factor 2D; Robo1: roundabout homolog 1; Ecop: EGFR-coamplified and -overexpressed protein; CDH2: N(Neural)-cadherin; ZEB2: zinc finger E-box-binding homeobox 2; EMT: epithelial-mesenchymal transition. Created in BioRender Thyagarajan A (2025).